Luzitin, S.A. is a pharmaceutical company focused on the pursuit of innovative solutions for photodynamic therapy (PDT) and photodiagnosis (PDD). Luzitin is open to different investment modalities, from equity sharing to licensing and/or co-development of its therapeutic solutions. There are three unique opportunities for partnership development of Redaporfin: Redaporfin combined with immune checkpoint inhibitors based on its meaningful in-vivo preclinical immunologic effects to treat melanoma. | Redaporfin to treat biliary tract cancer for which EMA has granted Orphan Drug Designation and for which a pivotal study is planned. This provides a further opportunity for fast track status. Application for Orphan Drug Designation by the FDA is planned for later in 2016. | Redaporfin to treat head and neck cancer in combination with immune checkpoint inhibitors.
View Top Employees from Luzitin SAWebsite | http://luzitin.pt |
Revenue | $5.6 million |
Employees | 3 (0 on RocketReach) |
Founded | 2010 |
Address | Edifício Bluepharma-Rua Da Bayer S. Martinho Do Bispo, Coimbra 3045-016, PT |
Phone | +351 239 800 300 |
Technologies |
JavaScript,
HTML,
Twitter
+15 more
(view full list)
|
Industry | Biotechnology, Research, Manufacturing General, Manufacturing, Science and Engineering, Drug Discovery, Health Care, Pharmaceutical |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies |
Looking for a particular Luzitin SA employee's phone or email?
The Luzitin SA annual revenue was $5.6 million in 2024.
The NAICS codes for Luzitin SA are [32, 3254, 325, 32541].
The SIC codes for Luzitin SA are [283, 28].